SCHEMBL1407290

SCHEMBL1407290

CC1CCN(C(=O)Nc2cccc(C#Cc3cccc(-c4c5cccc(C(F)(F)F)c5nn4Cc4c(F)cc(F)cc4F)c3)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
NR1H2 P55055 10/20 0.40
NR1H3 Q13133 10/20 0.40
NR1I2 O75469 2/20 0.40
NR3C1 P04150 2/20 0.40
AR P10275 1/20 0.38
RXRA P19793 1/20 0.38
TRPV1 Q8NER1 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
RECQL P46063 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MCHR1 Q99705 1/20 0.35
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407798 0.92 EPHX2 (0.38) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407826 0.91 NR1H2 (0.40) LMNANR1H2NR1H3NR1I2NR3C1
SCHEMBL1407515 0.89 ALDH1A1 (0.41) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL3858344 0.88 MAPT (0.39) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1408045 0.88 EPHX2 (0.40) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL3863906 0.87 NR1H2 (0.46) LMNANR1H2NR1H3NR1I2NR3C1
SCHEMBL1407353 0.86 NR1H2 (0.44) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407686 0.85 NR1H2 (0.43) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407727 0.84 NR1H2 (0.42) NR1H2NR1H3NR1I2NR3C1AR
SCHEMBL1407970 0.83 NR1H2 (0.41) NR1H2NR1H3NR1I2NR3C1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 LMNA 1326/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.